Agendia Launches TargetPrint for Breast Cancer Patients Optimizing Patient Identification for Targeted Therapies That Ensure Benefits of Personalized Treatment

Agendia, a world leader in molecular cancer diagnostics, today announced the launch of TargetPrint®, a new diagnostic test that allows physicians to quantitatively determine the gene expression levels of the estrogen receptor (ER), progesterone receptor (PR) and Human Epidermal growth factor Receptor 2 (HER2) in breast cancer tumor biopsies.

Source: Agendia